Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

A court in Baltimore has ordered Johnson & Johnson to pay $1.56 billion to a Maryland woman who claimed that her use of the company’s baby powder caused her cancer. It is the largest award ever ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

When looking back at one of the most disruptive years in biopharma in recent memory, sev | Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease ...

A six-month community awareness campaign has significantly increased colorectal cancer awareness in part of Nigeria, leading researchers to recommend expanding the model to the national level.

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...